Q-omics provides the consensus-scored NIBAN3 profile across patient tissues and cancer cell-line models. NIBAN3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NIBAN3 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, NIBAN3 RNA expression shows 14,583 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, BLCA, and TGCT as cancer lineages where NIBAN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIBAN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIBAN3 survival associations across molecular data types. NIBAN3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIBAN3 RNA expression–survival associations across cancer types. High NIBAN3 expression shows unfavorable associations in ACC, but favorable associations in HNSC, SKCM, LUAD, CESC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NIBAN3 RNA expression.
This table summarizes NIBAN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for NIBAN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIBAN3 shows lower tumor expression in BLCA, COAD, LUSC, PAAD and THCA and higher tumor expression in BRCA. The BLCA box plot shows higher NIBAN3 RNA expression in normal versus tumor tissue (log2 FC = −0.742, t-test p = .007).
This table shows molecular features associated with NIBAN3 in patient tissues and cancer cell lines. In patient samples, NIBAN3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NIBAN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
